Muscle loss in elder male residents of the community is associated with the severity of metabolic associated fatty liver disease

Abstract

Abstract: Objective To investigate the relationship between metabolic associated fatty liver disease (MAFLD) and muscle loss in elder male residents of the community.Methods A cross-sectional survey was conducted among 232 elderly male residents over 65 years old in a community in Beijing. Demographic data, medical history, physical examination and laboratory examination Results were collected for all subjects. Body composition was detected with body composition tester. Liver fat content and liver elasticity were examined by FibroScan. Muscle loss was defined as the ratio of skeletal muscle mass and weight (ASM%) less than 29.1. The patients were divided into a muscle loss group and a non-muscle loss group, and the differences in metabolic indicators, proportion and severity of MAFLD between the two groups were compared. The differences between the quartiles were compared using Chi-square test, one-way ANOVA analysis, and Kruskal-Wallis test.Results In all patients, age, BMI, body fat percentage, visceral fat area, hypersensitive C-reactive protein and glucose metabolism indexes in muscle loss group [ASM% (27.41±1.17)] were significantly higher than those in non-muscle loss group [ASM% (31.47±1.86)], ALT [24.0 (18.0, 33.0) vs. 20.0 (16.0, 26.0)], liver fat content [(290.4±60.4) vs. (256.4±53.6)], liver stiffness scores [(5.30 (4.20, 6.80) vs. 4.45 (3.80, 5.90)], basal metabolic rate, and HDL-C were lower than those in non-muscle loss group (all P<0.05). Patients in the lower ASM% quartile group had more significant metabolic disturbances and severe hepatic fatty changes than those in the higher ASM% quartile group. 76.9% of patients with MAFLD were in the muscle loss group and 50.3% in the non-muscle loss group (χ²=13.593, P<0.001). BMI, waist circumference, hip circumference, waist-hip ratio, upper arm circumference, body fat percentage, visceral fat area and controlled attenuation parameters (CAP) in patients with MAFLD combined with muscle loss were higher than those in the non-muscle loss group (all P<0.05).Conclusion In elder men, muscle loss is accompanied by more severe metabolic abnormalities and hepatic steatosis, suggesting that attention should be paid for the screening of elderly muscle loss and MAFLD to lay the foundation of timely diagnosis and early intervention.

Key words: Metabolic associated fatty liver disease, Sarcopenia, Community, Cross-sectional studies

ZHANG Shuang, LIU Xiao-hui, WANG Gang, ZHANG Li, WU Jian, ZHANG Jing. Muscle loss in elder male residents of the community is associated with the severity of metabolic associated fatty liver disease[J]. Chinese Hepatolgy, 2022, 27(11): 1206-1212.

References

[1] Chen L, Liu L, Woo J, et al. Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc, 2014, 15(2): 95-101.
[2] Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol, 2015, 63(2): 486-493.
[3] Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol, 2017, 66(1): 123-131.
[4] Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006, 43(6): 1317-1325.
[5] Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45(4): 846-854.
[6] Kim Y, Lee Y, Chung Y, et al. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. J Gerontol A Biol Sci Med Sci, 2012, 67(10): 1107-1113.
[7] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1): 202-209.
[8] Chen L, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc, 2020, 21(3): 300-307.
[9] 陈姝, 俞静, 狄文娟, 等. 南京市社区老年肌少症流行病学调查及其影响因素分析. 实用老年医学, 2020, 34: 793-796.
[10] Du Y, Wang X, Xie H, et al. Sex differences in the prevalence and adverse outcomes of sarcopenia and sarcopenic obesity in community dwelling elderly in East China using the AWGS criteria. BMC Endocr Disord, 2019, 19(1): 109.
[11] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing, 2019, 48(1): 16-31.
[12] Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014, 69(5): 547-558.
[13] Xia M, Chen L, Wu L, et al. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng Study. Aliment Pharmacol Ther, 2019, 50(6): 684-695.
[14] 刘颖, 杨继红, 施红, 等. 老年2型糖尿病患者肌少症与早期肾功能减退的关系. 中华老年医学杂志, 2021, 40: 34-38.
[15] Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care, 2010, 33(7): 1652-1654.
[16] He Q, Wang X, Yang C, et al. Metabolic and Nutritional Characteristics in Middle-Aged and Elderly Sarcopenia Patients with Type 2 Diabetes. J Diabetes Res, 2020, 2020: 6973469.
[17] Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2017, 45(4): 510-518.
[18] Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int, 2019, 13(6): 674-687.
[19] Steffl M, Bohannon RW, Sontakova L, et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging, 2017, 12: 835-845.
[20] Kim TN, Park MS, Ryu JY, et al. Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean Sarcopenic Obesity Study (KSOS). PLoS One, 2014, 9(12): e115407.
[21] Turcotte LP, Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys Ther, 2008, 88(11): 1279-1296.
[22] Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA, 2007, 104(31): 12587-12594.
[23] 曹子怡, 管理, 陈洁. 维生素D在改善NAFLD与肌少症中的共同作用机制. 肝脏, 2021, 26: 1046-1051.
[24] Zhai HL, Wang NJ, Han B, et al. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China). Br J Nutr, 2016, 115(8): 1352-1359.
[25] Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol, 2013, 59(3): 557-562.